Back to results
US 2015/0306174 A1Published application
Trimeric HIV Fusion Inhibitors for Treating or Preventing HIV Infection
AssigneeNew York Blood Center, Inc.
InventorsShibo Jiang, Zhi Qi, Xi Chen, Chungen Pan
Life of this patent
Estimating the term…
Abstract
Disclosed herein are trimeric polypeptide pharmaceutical compositions comprising three monomers, each monomer comprising a polypeptide having the amino acid sequence of the N-terminal heptad repeat (NHR or HR1) or C-terminal heptad repeat (CHR or HR2) of the transmembrane glycoprotein of human immunodeficiency virus (HIV) and a trimerization motif.
Claims10
A method of inhibiting the fusion of a human immunodeficiency virus (HIV) to a target cell comprising:
- administering a trimeric polypeptide pharmaceutical composition to the target cells, wherein the composition comprises a trimeric polypeptide, wherein the trimeric polypeptide comprises three polypeptide monomers, each polypeptide monomer consisting of a fusion peptide consisting of the amino acid sequence of the N-terminal heptad repeat (NHR or HR1) of the transmembrane glycoprotein gp41 of HIV fused to a foldon trimerization motif, wherein the NHR is N28, and wherein the foldon trimerization motif sequence is fused to the C-terminus of the NHR;
- and
- inhibiting fusion of the virus to the cell.
A method of treating infection with a human immunodeficiency virus (HIV) comprising:
- administering a trimeric polypeptide pharmaceutical composition to a subject infected with HIV, wherein the composition comprises a trimeric polypeptide, wherein the trimeric polypeptide comprises three polypeptide monomers, each polypeptide monomer consisting of a fusion peptide consisting of the amino acid sequence of the N-terminal heptad repeat (NHR or HR1) of the transmembrane glycoprotein gp41 of HIV fused to a foldon trimerization motif, wherein the NHR is N28, and wherein the foldon trimerization motif sequence is fused to the C-terminus of the NHR;
- and
- thereby treating the infection in the subject.
Dependencies are inferred from the claim text.